Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. Glenmark Pharmaceuticals Limited was incorporated on November 18 1977. Established in 1977, the company manufactures and distributes branded and generic formulations, active pharmaceutical ingredients (API's) and biosimilars. It has 18 manufacturing facilities in India, 7 in the U.S., 1 in Brazil and 1 in Mexico that span across the world catering to global requirements.
The company has established itself as a significant player in the pharmaceutical industry with a strong focus on research and development. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. 14th largest and fastest growing in the Indian market, 15th largest generic company by prescriptions filled in the USA, 5th largest Indian generic co. in Europe.
As of the latest available data, Glenmark Pharmaceuticals has a market cap of ₹50,367 crore (up 39.1% in 1 year) with revenue of ₹13,322 crore and profit of ₹1,047 crore as per FY24 figures. Promoter holding in Glenmark Pharmaceuticals Ltd has gone up to 46.65 per cent as of Mar 2025 from 46.65 per cent as of Jun 2024.
For Q4 FY25, Glenmark Pharmaceuticals reported revenue of Rs 2,704.03 Cr, up from Rs 2,520.28 Cr in March 2024. Net profit increased to Rs 253.57 Cr from Rs 190.60 Cr, with EPS rising to Rs 2.25 from Rs 1.91. Glenmark Pharmaceuticals Ltd reported a consolidated revenue growth of 12.8% for FY25, indicating strong overall performance.
The company's financial performance has shown positive momentum with key financial metrics demonstrating growth:
- For Q4FY24, Glenmark's consolidated revenue increased by 2.1 percent on a year-on-year basis to Rs 3,063 crore from Rs 3,000.5 crore. The company reported a rise in EBITDA at Rs 504.3 crore, a rise of 26.7 percent from the previous year's Rs 397.9 crore, with an EBITDA margin of 16.5 percent.
- For FY26, Glenmark is guiding for a revenue growth of 10% to 12% and an EBITDA margin of 19% to 20%, with expected cash generation of INR300 crores to INR400 crores.
Glenmark's revenue is diversified across multiple geographic markets, providing stability and growth opportunities. The company's India business posted a healthy growth of 12.9 percent to Rs 939.1 crore, while its Rest of the World (RoW) segment grew by 9.7 percent to Rs 752.8 crore. The European region saw a marginal uptick of 0.7 percent to Rs 611.8 crore, while the North American region experienced a 12.4 percent decline in revenue at Rs 755.7 crore. The Europe business showed robust growth, contributing 21.4% to the consolidated revenues, with a nearly 20% increase in Q4.
The Company is actively involved in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). The firm will invest significantly in research and development (R&D) to meet its revenue target and has allocated 7-7.25 percent of its total sales to R&D efforts. Glenmark has earmarked Rs 700 crore for consolidated capital expenditures (CAPEX) to bolster its operational infrastructure.
The company has been making significant strides in its innovation pipeline with strategic partnerships and licensing deals. The company secured an out-licensing deal for one of its assets in its innovation pipeline, OX40 antagonist monoclonal antibody portfolio, to Astria Therapeutics. This further strengthens its position as one of the leading research-led pharmaceutical companies from India. Discussions with multiple big pharma partners are progressing well for ISB 2001, and a licensing deal is expected soon, which could be transformational for Glenmark.
Glenmark has been actively expanding its product portfolio with several significant launches. Glenmark launches TEVIMBRA immuno-oncology drug in India for NSCLC and ESCC after CDSCO approval. Glenmark Pharmaceuticals launched TEVIMBRA, a lung cancer treatment, marking its entry into immune-oncology. Upcoming launches of oncology products like tezilizumab and zanubrutinib are expected to drive growth. Additionally, respiratory products and strong performance in dermatology and OTC segments will contribute to growth.
Pharmaceutical giant Glenmark Pharmaceuticals has outlined its roadmap for FY2025 focusing on growth and expanding global market presence. The pharma giant aims to achieve consolidated revenue between Rs 13,500 crore and Rs 14,000 crore, with a push towards market leadership and financial strength. Glenmark Pharmaceuticals is enhancing its skincare market presence through a blend of prescription and OTC products, leveraging dermatological recommendations and modern retail, including e-commerce.
The company has implemented strategic changes to improve operational efficiency. During Q3, the company implemented changes in the overall distribution model of its India business through the consolidation of stock points and the rationalisation of channel inventories leading to a temporary dip in sales during the quarter. Going forward, this will help improve the company's operating margins and overall working capital.
The company is led by Glenn Saldanha as Chairperson. Recent appointment of Anurag Mantri as Executive Director & Global CFO for five years from May 27, 2025. The company maintains transparency in its operations and has been recognized for its workplace culture. The Company has also been Great Place To Work® Certified™ in India for FY 2023.
Glenmark Pharmaceuticals continues to strengthen its position as a leading pharmaceutical company with a robust pipeline, diversified geographic presence, and strong commitment to innovation and sustainable growth in the global healthcare market.
